… D., and AP Bryant, MS, under instructions from the Director of this Office. This compilation is
a revision of an earlier bulletin of this Office bearing the same title. Since the first edition was …

A genomics‐based approach was used to identify the entire gene complement of putative
two‐component signal transduction systems (TCSTSs) in Streptococcus pneumoniae. A total …

The mevalonate pathway and the glyceraldehyde 3-phosphate (GAP)–pyruvate pathway
are alternative routes for the biosynthesis of the central isoprenoid precursor, isopentenyl …

Streptococcus pneumoniae remains a serious cause of morbidity and mortality in humans,
but relatively little is known about the molecular basis of its pathogenesis. We used signature‐…

… A P value < 0.05 is considered statistically significant. … shown that this transmembrane
receptor is the molecular target of linaclotide (Bryant et al., 2010). The affinity of linaclotide for …

Background Linaclotide is a novel, orally administered investigational drug currently in clinical
development for the treatment of constipation‐predominant irritable bowel syndrome (IBS‐…

… Bryant a , Robert W. Busby a , Wilmin P. Bartolini a , Etchell A. … A P value < 0.05 is
considered statistically significant. … Cohen, AP Bryant, C. Kurtz, MG Currie, EA Mayer, L. Bueno …

Activation of guanylate cyclase-C (GC-C) expressed predominantly on intestinal epithelial
cells by guanylin, uroguanylin or the closely related GC-C agonist peptide, linaclotide, …

Linaclotide, a potent guanylate cyclase C agonist, is a therapeutic peptide approved in the
United States for the treatment of irritable bowel syndrome with constipation and chronic …

… targeting this key developmental process (13; AP Bryant, CM Butler, A. Fretzen, AL Lazzell,
AW Monreal, C. Monteagudo, EO Solberg, JL Lopez-Ribot, SP Saville, and GT Milne, Abstr. …